期刊文献+

乳腺癌21基因检测研究进展 被引量:2

下载PDF
导出
摘要 乳腺癌已成为威胁女性健康最常见的癌症之一,随着对乳腺癌的进一步研究,其治疗模式发生了巨大的变化。目前的治疗模式为在手术的基础上,辅以放疗、化疗、内分泌治疗或联合治疗。那么,面对不同的患者,临床医师该如何选择最适合患者肿瘤特性的治疗方案呢?随着基因技术的发展.科学家们将目光转向了临床分子生物学研究中的“基因表达谱”上,乳腺癌的研究可以说是最早启动的一批癌症研究项目。
出处 《泸州医学院学报》 2016年第6期589-591,共3页 Journal of Luzhou Medical College
  • 相关文献

参考文献1

二级参考文献35

  • 1Fisher B, Costantino J, Redmond C, et al. A randomized clinical tri- al evaluating tamoxifen in the treatment of patients with node - neg- ative breast cancer who have estrogen - receptor - positive tumors [J]. N Engl J Med,1989,320(8) :479 -484.
  • 2Scottish Cancer Trials Office ( MRC ). Adjuvant tamoxifen in the management of operable breast cancer [ J]. Lancet, 1987, 2 (8552) :171 - 174.
  • 3Nolvadex Adjuvant Trial Organization. Controlled trial of tamoxifen as a single agent in management of early breast cancer; analysis at six years by Nolvadex Adjuvant Trial Organisation [ J ]. Lancet, 1985,1 (8433) :836 - 839.
  • 4Stewart HJ. The Scottish trial of adjuvant tamoxifen in node - nega- tive breast cancer. Scottish Cancer Trials Breast Group [ J ]. J Natl Cancer Inst Monogr, 1992,11 : 117 - 120.
  • 5Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node - negative, estrogen receptor - positive breast cancer [ J ]. J Natl Cancer Inst, 1997,89 (22) : 1673 - 1682.
  • 6Fisher B, Jeong JH, Anderson S, et al. Treatment of axillary lymph node - negative, estrogen receptor - negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials[J]. J Natl Cancer Inst,2004,96(24) :1823 -1831.
  • 7Paik S, Shak S, Tang G, et al. A multigene assay to predict recur- rence of tamoxifen - treated, node - rlegative breast cancer [ J ]. N Engl J Med,2004,351 (27) :2817 -2826.
  • 8Paik S,Tang G,Shak S, et al. Gene expression and benefit of chem- otherapy in women with node - negative, estrogen receptor - posi- tive breast cancer[ J ]. J C lin Onco1,2006,24 (23) :3726- 3734.
  • 9Mamounas EP, Tang G, Fisher B, et al. Association between the 21 - gene recurrence score assay and risk of locoregional recurrence in node - negative, estrogen receptor - positive breast cancer: results from NSABP B - 14 and NSABP B -20[J]. J Clin Oncol,2010,28 (10) :1677 - 1683.
  • 10Toi M, lwata H, Yamanaka T, et al. Clinical significance of the 21 - gene signature ( oncotype DX) in hormone receptor - positive early stage primary breast cancer in the japanese population [ J ]. Cancer,2010,116(13) :3112 -3118.

共引文献7

同被引文献7

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部